Valeant Pharmaceuticals Acquires Bausch + Lomb for $8.7 Billion
In a blockbuster deal that may reshape the eye care
landscape, Canadian drugmaker Valeant Pharmaceuticals
International Inc. announced it will acquire Bausch + Lomb
for $8.7 billion in cash.
Under the terms of the agreement, Valeant will pay
about $4.5 billion to an investor group led by Bausch +
Lomb owner Warburg ...